The Cyclocapnic Method for Measurement of Chemosensitivity

Imperial College London

Status and phase

Unknown

Phase 1

Conditions

Periodic Breathing

Heart Failure

Treatments

Other: carbon dioxide

Study type

Interventional

Funder types

Other

Identifiers

NCT01049256

07/H0712/129

Details and patient eligibility

About

We aim to test our method for measuring chemosensitivity (the ventilatory response to a change in carbon dioxide), which uses sinusoidal carbon dioxide stimuli.

Hypotheses:

Carbon dioxide sensitivity is dependent on the cycle time over which we administer the gas (frequency).
Chemoreflex gain decreases as deadspace increases.

Full description

We will apply a new method for the measurement of chemosensitivity (how sensitive a person is to changes in carbon dioxide), which is one of the principle determinants of whether people with heart failure develop abnormal breathing patterns We have shown in a pilot study that administering sinusoidal patterns of inspired carbon dioxide produces similar sinusoidal responses in ventilation. We aim to test our method for measuring chemosensitivity, which uses sinusoidal carbon dioxide stimuli (similar to those that drive the oscillations in ventilation found in periodic breathing). We aim to show that how the cycle time of carbon dioxide administered affects the resulting ventilatory oscillations and therefore that when measuring the chemoreflex clinically, it is important to deliver carbon dioxide stimuli that replicate the cycle time of oscillations in carbon dioxide seen in periodic breathing (typically approximately one minute).

Enrollment

45 estimated patients

Sex

Male

Ages

18 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Heart failure subjects with stable cardiorespiratory control to be recruited from our institution's specialist heart failure clinic.
Normal healthy volunteers, with normal systolic function.

Exclusion criteria

We will exclude patients with chronic respiratory disease (every patient will have formal lung function testing on entrance into the study) or unstable coronary artery disease (myocardial infarction or unstable angina within the past 3 months).
In addition any subjects receiving treatment with morphine and derivatives, theophylline, oxygen, benzodiazepines or acetazolamide will be excluded as these affect chemosensitivity.